The encouraging results discussed above, including the tendency to restore the deranged metabolic profile, the decrease in senescence-related markers, and the amelioration trend of the inflammatory process, lead us to think of the possible use of a PPARγ agonist in the treatment of vitiligo. This evidence concerns the gene PPARG and vitiligo.